One year ago today, Circle became the first major global issuer to achieve compliance under the EU’s landmark MiCA framework.We didn’t stop there.https://t.co/YWC9Tc2ss8 https://t.co/6DRxC2Gem9 ...

Key Takeaways The Supreme Court declined to hear XOM's appeal over a $14.25M Clean Air Act pollution penalty. The case stems from repeated Baytown emissions violations from 2005 to 2013. XOM argued plaintiffs lacked standing, but lower court rulings and precedent were upheld.Exxon Mobil Corporation (XOM) has suffered a legal blow after the U.S. Supreme Court declined to hear its appeal challenging a $14.25 million civil penalty linked to air pollution violations at its massive Baytown refinery complex in ...

Core Viewpoint - Credicorp Ltd. initiates legal action against the Peruvian Tax Administration (SUNAT) for disregarding legal norms and decisions made by SUNAT's Review Committee, which undermines legal certainty for companies operating in Peru [1][4]. Group 1: Legal Action and Tax Dispute - The legal action is in response to SUNAT's reopening of a case regarding transactions from 2018 and 2019, where Grupo Crédito S.A. purchased Banco de Crédito del Perú (BCP) shares from Credicorp Ltd. [2][4]. - SUNAT is seeking over S/. 1.5 billion in alleged unpaid income tax and accrued interest, despite the Review Committee's previous confirmation of the transactions' authenticity and compliance with tax laws [4]. Group 2: Compliance and Regulatory Framework - The transactions were communicated to the Superintendencia del Mercado de Valores (SMV), approved by the Superintendencia de Banca, Seguros y AFP (SBS), and registered with Registro Central de Valores y Liquidaciones (CAVALI), indicating full compliance with legal and regulatory requirements [3]. - Grupo Crédito S.A. reaffirms its commitment to regulatory and tax compliance, emphasizing the protection of its employees, clients, and investors [5]. Group 3: Company Overview - Credicorp is the leading financial services holding company in Peru, with operations in Chile, Colombia, Bolivia, and Panama, and has a diversified business portfolio across Universal Banking, Microfinance, Insurance & Pension Funds, and Investment Management & Advisory [6].

UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following ...

Core Insights - The survey conducted by Kompliant and Equifax reveals that financial organizations are transforming compliance from a cost center into a revenue driver through intelligent solutions [2][4] - A significant 55% of financial firms are exploring or implementing AI/ML technologies for compliance functions, indicating a strong trend towards automation in the industry [5] Group 1: Compliance Strategy and Technology Adoption - 56% of financial organizations involve their CEO directly in compliance technology decisions, highlighting the strategic importance of these investments [5] - 90% of institutions believe that technological advancement is critical for maintaining a competitive advantage in risk management [5] - 99% of financial services organizations now rely on compliance technology, showcasing its integral role in operations [5] Group 2: Emerging Technologies and Concerns - 55% of financial firms are exploring or implementing AI/ML for compliance functions, making it the top emerging technology in the sector [5] - 50% of organizations seek real-time risk monitoring capabilities, while 47% desire advanced AI analytics [5] - 68% of financial organizations remain cautious about adopting emerging technologies due to security concerns [5] Group 3: Industry Context and Future Directions - The survey comes at a critical time as the financial services industry faces increasingly complex regulations and transformative technological innovations [3] - The partnership between Kompliant and Equifax aims to deliver industry-leading fraud prevention and risk management services, addressing the need for intuitive compliance programs [4]

Group 1: Strategic Collaboration - ABeam Consulting (USA) Ltd. and Millennium EBS have signed a Master Services Agreement to promote the Millennium EBS Payment Hub: ISO 20022 Transformer, combining ABeam's expertise in business transformation with Millennium EBS's payment technology [1][2] - The collaboration aims to provide banks and financial institutions with a streamlined solution for ISO 20022 compliance, addressing the increasing pressure for migration to new messaging standards [2][3] Group 2: Benefits of ISO 20022 Transformer - The ISO 20022 Transformer facilitates seamless integration with legacy systems, ensuring compliance with evolving regulations and enhancing data quality and process efficiency [2][4] - Financial institutions can achieve greater operational efficiency in both domestic and cross-border payments through the implementation of the ISO 20022 Transformer [5][8] Group 3: Company Profiles - ABeam Consulting has over 42 years of experience and operates in 36 countries, serving more than 750 clients with a reported revenue of $1 billion for fiscal year 2024 [6][7] - Millennium EBS, a subsidiary of BlueOne Card Inc., has over two decades of experience in delivering reliable payment solutions and focuses on empowering small to medium-sized banks with regulatory-compliant ISO 20022 transformation [10]

Company Compliance - Rocky Mountain Chocolate Factory, Inc. has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its Annual Report on Form 10-K for the fiscal year ended February 28, 2025 [1] - The company received a notice from Nasdaq on June 17, 2025, indicating non-compliance due to the delayed filing of its Form 10-K [2] - The Form 10-K was filed on June 20, 2025, and compliance was confirmed by Nasdaq on June 23, 2025 [2] Company Overview - Rocky Mountain Chocolate Factory, Inc. is a leading franchiser of premium chocolate and confectionary retail stores, producing a wide range of products since 1981 [3] - The company operates nearly 260 stores across the United States and has several international locations [3] - It is recognized in Entrepreneur's Franchise 500 for 2025 and Franchise Times' Franchise 400 for 2024 [3]

Core Viewpoint - SeaStar Medical Holding Corporation has undertaken several transactions to ensure compliance with Nasdaq's continued listing standards after receiving a notification regarding non-compliance with market value requirements [2][3]. Group 1: Compliance and Financial Transactions - SeaStar Medical received a notification from Nasdaq on June 24, 2024, indicating non-compliance with the minimum market value requirement of $35 million [2]. - The Nasdaq Hearings Panel granted an extension until June 22, 2025, for the company to demonstrate compliance with an alternative requirement of $2.5 million in stockholders' equity [2]. - The company completed a $4.0 million public offering of common stock and warrants on June 23, 2025, and entered into a purchase agreement with Lincoln Park Capital for up to $15.0 million in common stock purchases over three years [6]. Group 2: Business Operations and Product Development - SeaStar Medical increased its customer count to six for its FDA-approved product, QUELIMMUNE, which reduces pediatric mortality by approximately 50% in patients with multiple organ failure [3][4]. - The company initiated a cost-cutting program in May 2025, expected to reduce operating expenses for the remainder of the fiscal year without materially impacting operations [3]. - Approximately $1.2 million in employee compensation and director fee liabilities were extinguished as certain employees and directors waived their rights to unpaid bonuses and fees [3]. Group 3: Product Overview and Clinical Trials - QUELIMMUNE therapy is designed for children with acute kidney injury (AKI) and sepsis, approved under a Humanitarian Device Exemption in February 2024, and launched commercially in July 2024 [4][10]. - The NEUTRALIZE-AKI pivotal trial is evaluating the safety and efficacy of the Selective Cytopheretic Device (SCD) therapy in 200 adults with AKI, focusing on 90-day mortality and dialysis dependency as primary endpoints [7]. - The SCD therapy aims to neutralize over-active immune cells and mitigate hyperinflammation, with potential applications in various acute and chronic kidney and cardiovascular diseases [9][10].

Veriforce® brings end-to-end contractor management, safety verification, and workforce training support to leading independent oil and gas producerTHE WOODLANDS, Texas, June 24, 2025 /PRNewswire/ -- Veriforce, the largest global provider of contractor management and workforce qualification solutions, announced today that Ring Energy Inc., a rapidly growing oil and gas exploration and production company, has selected Veriforce as its exclusive contractor management provider. Through this partnership, Verifor ...

What what is this latest injectable. Why is it better. It's a milestone moment, Becky, in in the history of HIV.Yes. Tuggo is is potentially the best tool we've had yet and and a number of great tools that could potentially end the epidemic. And the reason why is this is a first of its kind.Um medicine for preventing HIV that's given only twice a year. Uh and in clinical trials, it provided almost 100% protection against HIV, which is really unheard of. So, it's a it's one of the most important scientific b ...